Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors.

摘要

To the Editor The advent of drugs targeting the ubiquitous vascular endothelial growth factor (VEGF) signalling pathway has been a breakthrough in anticancer therapeutics. Several drug classes contribute to this new clinical group: orally bioavailable small-molecule inhibitors of VEGF receptors, such as sunitinib; antibodies to the VEGF ligand (bevacizu-mab); antibodies to the extracellular domains of VEGF receptors; or decoy fusion receptors, such as aflibercept.